Age-related heterogeneity in neutralising antibody responses to SARS-CoV-2 following BNT162b2 vaccination

DA Collier, IATM Ferreira, R Datir, B Meng… - MedRxiv, 2021 - medrxiv.org
Background Vaccines remain the cornerstone for containing the SARS-CoV-2 pandemic.
mRNA vaccines provide protection in clinical trials using a two-dose approach, separated by
a three to four week gap. UK policy in 2021 is to extend the dosing interval from three to
twelve weeks. There is a paucity of data in the elderly, even though these individuals are the
first to receive vaccines due to risk of severe disease. Here we assessed real world immune
responses following vaccination with mRNA-based vaccine BNT162b2. Methods We did a …

[PDF][PDF] Age-related heterogeneity in Neutralising antibody responses to SARS-CoV-2 following BNT162b2 vaccination

M Wills, RK Gupta - scholar.archive.org
1Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge,
UK. 2Department of Medicine, University of Cambridge, Cambridge, UK. 3Division of
Infection and Immunity, University College London, London, UK. 4The CITIID-NIHR
BioResource COVID-19 Collaboration, see appendix 1 for author list 5NIHR Cambridge
Clinical Research Facility, Cambridge, UK. 6Department of Clinical Biochemistry and
Immunology, Addenbrookes Hospital, UK 7 Laboratorio de Inmunologia, S-Cuautitlán …
以上显示的是最相近的搜索结果。 查看全部搜索结果